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ABSTRACT
Motivation: Statistical methods are used to test for the differential
expression of genes in microarray experiments. The most widely
used methods successfully test whether the true differential
expression is different from zero, but give no assurance that the
differences found are large enough to be biologically meaningful.
Results: We present a method, t-tests relative to a threshold
(TREAT), that allows researchers to test formally the hypothesis (with
associated p-values) that the differential expression in a microarray
experiment is greater than a given (biologically meaningful) threshold.
We have evaluated the method using simulated data, a dataset from a
quality control experiment for microarrays and data from a biological
experiment investigating histone deacetylase inhibitors. When the
magnitude of differential expression is taken into account, TREAT
improves upon the false discovery rate of existing methods and
identiﬁes more biologically relevant genes.
Availability: R code implementing our methods is contributed to the
software package limma available at http://www.bioconductor.org.
Contact: smyth@wehi.edu.au
1 INTRODUCTION
In gene expression analysis, what does it mean to claim that
a gene is differentially expressed? In formal statistical terms, a
gene is differentially expressed if its expression level changes
systematically between two treatment conditions, regardless of how
small the difference might be. On the other hand, in scientiﬁc
discussion, a gene is likely to be considered differentially expressed
only if its expression level changes by a worthwhile amount.
There is therefore a disconnect between the mathematical and
biological concepts of differential expression. In this article, we
move the concept of statistical signiﬁcance to be closer to the
biological concept of differential expression.
The earliest microarray publications judged differential
expression purely in terms of fold-change (DeRisi et al., 1996;
Schena et al., 1996), with 2-fold typically considered a worthwhile
cutoff. However, fold-change cutoffs do not take variability into
account or guarantee reproducibility, so it soon become popular to
use traditional statistical tests such as the t-test or the Wilcoxon
test. These in turn were soon found to give high false discovery
rates (FDRs) in small samples, and to be only weakly related to
fold-change.
∗To whom correspondence should be addressed.
A new generation of statistical tests has been developed for
the microarray context in recent years, introducing tests that
borrow information between genes using empirical Bayes and
other statistical means (Baldi and Long, 2001; Efron et al., 2001;
Lönnstedt and Speed, 2002; Smyth, 2004; Tusher et al., 2001;
Wright and Simon, 2003). These tests have been consistently shown
to outperform traditional genewise statistical tests, and to give
results more in line with fold-change rankings (Jeffery et al., 2006;
Kooperberg et al., 2005; Shi et al., 2005; Xie et al., 2004).
However, even these modern statistical tests permit genes
with arbitrarily small fold-changes to be considered statistically
signiﬁcant. Hence, it has become increasingly common to require
that differentially expressed genes satisfy both p-value and fold-
change criteria simultaneously. Patterson et al. (2006) required
genes to satisfy a modest level of statistical signiﬁcance (p<0.01
or p<0.05) then ranked signiﬁcant genes by fold-change with a
cutoff of 1.5, 2 or 4. They found that this combination ranking
gave much better agreement between platforms than p-value alone.
Other studies have applied a fold-change cutoff and then ranked by
p-value. Peart et al. (2005) and Raouf et al. (2008) declare genes
to be differentially expressed if they show a fold-change of at least
1.5 and also satisfy p<0.05 after adjustment for multiple testing.
Huggins et al. (2008) required a 1.3 fold-change and p<0.2. These
combinationcriteriatypicallyﬁndmorebiologicallymeaningfulsets
of genes than p-values alone.
The combination approaches remain ad hoc. If the FDR is
controlled at a certain level using p-values, but a fold-change cutoff
is applied as well, then the expected FDR must decrease, but by how
much is unclear. At the same time, the fold-change cutoff does not
take variability into account, so there is no statistical conﬁdence
that the genes will achieve the same fold-change threshold in
future experiments or studies. Hence, a more formal approach for
combining statistical signiﬁcance and fold-change is desirable.
We present a new method for assessing differential expression
in microarray experiments, t-tests relative to a threshold (TREAT).
This method is an extension of the empirical Bayes moderated
t-statisticpresentedbySmyth(2004),andcanbeusedtotestwhether
the true differential expression is greater than a given threshold
value. By including the fold-change threshold of interest in a formal
hypothesis test, we achieve reliable p-values and FDRs for ﬁnding
genes with differential expression that is biologically meaningful.
The biological signiﬁcance of a given fold-change is likely to
depend on the gene and on the experimental context. On the other
hand, it is reasonable to assume that there is a minimum fold-change
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threshold below which differential expression is unlikely to be of
interest for any gene. We assume throughout this article that such a
minimum fold-change threshold can be speciﬁed for the experiment
at hand.
2 APPROACH
2.1 Hypotheses relative to a threshold
Letβg bethelog-fold-changeforgenegrelatingtosomecomparison
of interest. In the simplest case, βg might be the log-fold-change
in expression between two treatment groups or between affected
and unaffected patients. The classical test of differential expression
would test the null hypothesis H0: βg=0 against the alternative
H1: βg =0. We test instead the thresholded null hypothesis that
H0: |βg|≤τ against the alternative H1: |βg|>τ, where τ is a pre-
speciﬁed threshold for the log-fold-change below which differential
expression is not of material interest.
Note that standard statistical theory does not provide an exact test
of the thresholded null hypothesis, even for normally distributed
data. The thresholded null hypothesis is a composite hypothesis in
that it speciﬁes an interval of values for βg rather than a single value
(Cox and Hinkley, 1974). The standard statistical approach would
be to construct a likelihood ratio test of H0 versus H1, and then to
applyasymptoticdistributiontheory.Ouraim,however,istoborrow
information between genes, and to calculate an exact p-value for the
thresholded test.
2.2 Linear models for microarray data
In order to be completely general, we adopt the linear model setup
of Smyth (2004). In this approach, the design of any microarray
experiment can be represented in terms of a linear model for each
gene. Assume that we have a set of n independent microarrays
yielding a response vector yT
g =

yg1,...,ygn

for the g-th gene. The
responses are assumed to be suitably normalized and will usually be
log-ratios for two-colour data or log-intensities for single-channel
data. Assume that
E(yg)=Xαg
where X is a design matrix of full column rank and αg is an
unknown coefﬁcient vector. The experimental design is captured
by the matrix X. For example, for a simple two-group comparison,
X wouldcontaintwocolumns,oneaninterceptcolumnandtheother
an indicator vector for the two groups.
We assume
var

yg

=Wgσ2
g
whereσ2
g istheunknowngenewisevarianceandWg isaknownnon-
negative deﬁnite weight matrix. The weights W may for example
represent quality weights for the individual observations.
Suppose that the contrast we wish to test is βg=cTαg, where
c is a constant vector. For example, in the two-group comparison,
we might have cT =(0,1) to pick out the coefﬁcient relating to the
difference between the two groups.
The linear model is ﬁtted to the responses for each gene to obtain
coefﬁcient estimator ˆ αg and variance estimator s2
g of σ2
g. The ﬁtting
might be by least squares, or perhaps by a robust estimation criteria,
but in any case the covariance of the coefﬁcients can be written
var

ˆ αg

=Vgσ2
g
where Vg is a positive deﬁnite matrix not depending on σ2
g. If the
ﬁttingofthelinearmodelisbyleastsquares,thenVg=(XTWgX)−1.
The corresponding estimate for βg is ˆ βg=cT ˆ αg.
The responses yg are not necessarily assumed to be normal and
the ﬁtting of the linear model is not assumed to be by least squares.
Nevertheless, we do assume ˆ βg to be approximately normal with
mean βg and the residual variances s2
g to follow approximately a
scaled χ2-distribution. The distributional assumptions we make can
be summarized by
ˆ βg|βg,σ2
g ∼N

βg,vgσ2
g

,
where vg=cTVgc, and
s2
g|σ2
g ∼
σ2
g
dg
χ2
dg
where dg is the residual degrees of freedom for the linear model for
gene g. Under these assumptions the ordinary t-statistic
tg=
ˆ βg
sg
√vg
follows a t-distribution on dg degrees of freedom.
2.3 Hierarchical model
The same linear model is ﬁtted to each gene, resulting in a large
number of ﬁts with the same structure. A simple hierarchical model
can reﬂect this parallel structure by describing how the unknown
coefﬁcients and variances vary across genes (Lönnstedt and Speed,
2002; Smyth, 2004; Wright and Simon, 2003). This is achieved by
assuming prior distributions for these sets of parameters.
Assume an inverse-χ2 prior for σ2
g located at prior estimate s2
0
with d0 degrees of freedom, i.e.
1
σ2
g
∼
1
d0s2
0
χ2
d0. (1)
This describes how the variances are expected to vary across genes.
Under this hierarchical model, the posterior mean of σ−2
g given
s2
g is
˜ s2
g=
d0s2
0+dgs2
g
d0+dg
.
The posterior variances shrink the observed variances towards the
prior value with the degree of shrinkage depending on the relative
sizes of the observed and prior degrees of freedom. Smyth (2004)
deﬁnes the moderated t-statistic by
˜ tg=
ˆ βg
˜ sg
√vg
. (2)
This statistic represents a hybrid classical and Bayesian approach in
which the posterior variance has been substituted into the classical
t-statistic in place of the usual sample variance. Under the null
hypothesis that βg=0, the moderated t follows a t-distribution on
dg+d0 degreesoffreedom(Smyth,2004;WrightandSimon,2003).
Furthermore, ˜ tg and ˜ sg are distributed independently of one another
(Smyth, 2004), a feature we will use below. The increased degrees
of freedom for the moderated over the ordinary t-statistic reﬂects the
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extrainformationborrowedfromtheensembleofgenesforinference
about each individual gene.
2.4 Testing relative to a threshold
Consider now the thresholded hypotheses deﬁned above, and write
tobs for the observed value of the moderated t-statistic ˜ tg. We wish
to obtain an expression for the p-value P(|˜ tg|≥tobs) given H0.
First observe that if βg=β0, then the re-centered t-statistic
˜ tg(β0)=
ˆ βg−β0
˜ sg
√vg
inherits the properties of the moderated t-statistic, following a
t-distribution on d0+dg independently of ˜ sg.
Note also that the distribution of ˜ sg does not depend on βg, our
parameterofinterest(Smyth,2004).Inotherwords, ˜ sg isanancillary
statistic. It is a general principle that test statistics can be made more
precise, with gain of statistical power, by conditioning on ancillary
statistics (Cox and Hinkley, 1974). Hence, we compute p-values
conditional on ˜ sg.
Without loss of generality, assume tobs >0. Write ˆ βobs for the
observed value of ˆ βg. The conditional p-value is deﬁned by
p=P(|˜ tg|>tobs|H0,˜ sg)
This probability is problematic to calculate because H0 refers to an
interval of possible values for βg. However, an upper bound can be
found by choosing that element of H0 which is the most difﬁcult to
reject. Thus, the conditional p-value can be bounded above by
p≤P(

˜ tg

>tobs|βg=β0,˜ sg)
where β0 is the value of the null hypothesis closest to ˆ βobs, i.e. β0=
min(τ, ˆ βobs). We adopt this upper bound as our p-value estimate,
understanding that, being a worst-case calculation, it is somewhat
conservative. It can be expanded as the sum of two tail probabilities
P(˜ tg<−tobs|βg=β0,˜ sg)+P(˜ tg>tobs|βg=β0,˜ sg)
Write
δ=
β0
˜ sg
√vg
.
Note that ˜ tg=tg(β0)+δ and that δ can be treated as a constant,
conditional on ˜ sg. Our conservative p-value is therefore the sum of
two t-distribution tail probabilities,
P(tg(β0)<−tobs−δ|βg=β0,˜ sg)
+P(tg(β0)>tobs−δ|βg=β0,˜ sg)
=F(tobs+δ)+F(tobs−δ)
where F() is the upper-tail probability function of the t-distribution
on d0+dg degrees of freedom. This yields an easily computable
conservative p-value for testing the thresholded null hypothesis. We
call the resulting statistical test TREAT.
3 RESULTS
3.1 Comparisons
We compared TREAT with ﬁve other methods for ranking
genes in terms of evidence for differential expression. The six
methods were compared in situations where the magnitude of the
differential expression was taken into account. Only genes with
‘true’differential expression greater than a threshold τ were deemed
to be differentially expressed. Knowledge of which genes are ‘truly’
differentially expressed and which are not, allows us to compare the
methods on the basis of FDR and the area under a receiver operating
characteristic (ROC) curve. TREAT is compared with the
(1) ordinary t-statistic;
(2) moderated t-statistic;
(3) ordinary fold-change;
(4) fold-change with moderated t-value cutoff; and
(5) moderated t with fold-change cutoff.
Methods (4) and (5) are ad hoc methods that attempt to combine
moderated t and fold-change. Both reﬂect approaches used in
practice. For method (5), genes are ordered on the magnitude of the
moderated t-statistic, but only genes with a fold-change greater than
the given threshold value are considered differentially expressed,
equivalent to the method used by Peart et al. (2005). Method (4)
is similar, but opposite—genes are ordered on the absolute value
of the log-fold-change, but genes with adjusted p-values from the
moderated t-statistic less than a given cutoff value (usually <0.05)
are ranked higher than genes with adjusted p-values larger than the
cutoff. Any method of adjusting the p-values for multiple testing
can be used; in the following analyses, we use the method described
by Benjamini and Hochberg (1995). Patterson et al. (2006) take a
similar approach to method (4), although without adjusting p-values
for multiple testing.
3.2 Simulated data
Using the distributional assumptions presented above, we simulated
1000 realizations of a microarray experiment involving 15000
genes. Parameter values were selected to reﬂect realistic values for a
typical microarray experiment. For each dataset, we ﬁrst simulated
values for σ2
g, the true variance of each gene, from the assumed
distribution given in (1). We set d0=4 and s0=0.07. These values
for σ2
g were then used to generate some random values for βg from a
normal distribution with mean of zero and variance of v0σ2
g, where
v0=8. Genes with a βg>log21.5, i.e. a fold-change >1.5, were
deﬁned as differentially expressed.
These values for βg were used to give the ‘true’ βg-values for
our simulation. We set 60% of the 15000 genes are set to have
true βg=0, and the remaining 40% have true βg-values taken from
the simulated set above—some of these 40% of genes are truly
differentiallyexpressedunderourdeﬁnition,i.e.havefold-change>
1.5, and the rest are deﬁned as not differentially expressed, although
their true βg is non-zero. On average, about 4% of the genes in each
dataset were deﬁned as truly differentially expressed.
The ‘observed’ values ˆ βg and s2
g are then simulated according to
the assumptions in Section 2.2, using our simulated ‘true’values for
βg and σ2
g, and with v1=(1/n1+1/n2), n1=n2=2 and dg=2.This
simulates a two-group comparison with two arrays in each group.
These ‘observed’ values were then analysed using the six different
methods described above.
The ‘true’ expression levels of the genes were known in this
simulation, so we could calculate the true FDR and the area under
the ROC curve for each of the six methods. Each method ranks
genes in order of evidence of differential expression. We ﬁnd
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Fig. 1. FDRs for six different gene selection statistics from the analysis of
simulated data. The rates are the means of actual FDRs for 1000 simulated
datasets.
the number of genes that are not truly differentially expressed in
a given number of genes as ranked by each method to give the FDR.
The number of false discoveries for each number of genes selected
as being differentially expressed and the area under the ROC curve
for each method was averaged over the 1000 runs to provide good
information on the performance of each statistic. For this analysis,
we set the threshold value for TREAT to τ =log21.5, and set the
p-value cutoff for method (4) to be an adjusted p-value of 0.05, and
the fold-change cutoff for method (5) to 1.5.
Figure 1 shows that, when used to analyse the simulated data,
TREAT has the lowest FDR overall. In general, the statistics based
onmoderatedt dobestforsmallnumbersofgenes,whereasmethods
based on fold-change do best for large numbers of genes. TREAT
successfully combines the advantages of both types of statistic,
matching the best statistics at the two extremes, and having clearly
lowest FDR of all the methods for the intermediate range of 250–
500 genes selected.Above about 600 genes selected, all the methods
whichusefold-changearesimilar.Table1showsthatTREAThasthe
highest area under the ROC curve, conﬁrming it is the best overall
method for these data. Ordinary t is by far the worst-performing
method.
3.3 Quality control data
We also used data from a real experiment to compare the different
methods. The dataset consists of 100 replicate two-colour cDNA
arrays from an experiment done at the Peter MacCallum Cancer
Centre designed for quality control of the microarray platform
being used (Ritchie et al., 2006). One array which contained some
missing values was discarded. Each array was printed with 10944
human probes and was hybridized with Jurkat (Cy3) and MCF7
(Cy5) RNA. The two samples used are from different cell-types,
so atypically for a microarray experiment, most of the genes are
Table 1. Area under the ROC curve for six methods and two datasets, one
simulated and the other real experimental data from the Peter MacCallum
Cancer Centre (PMCC)
Method Simulated data PMCC data
Ordinary t 0.9526 0.7852
Moderated t 0.9919 0.9723
Fold-change 0.9967 0.9819
Fold-change with moderated t cutoff 0.9963 0.9801
Moderated t with fold-change cutoff 0.9944 0.9761
TREAT 0.9970 0.9832
TREAThasthehighestareaundertheROCcurve(valuesinbold)forboththesimulated
data and the data from the PMCC quality control experiment.
differentially expressed. We compared methods by analysing two
randomlyselectedarraysforeachof1000runs.‘Truly’differentially
expressed genes were determined for each run by constructing 95%
conﬁdenceintervalsforthetrueexpressionlevelsusingthe97arrays
not used for analysis in that particular run.
As there was a great deal of differential expression for these
arrays, we set our threshold value to τ =log22. Genes were ﬂagged
as differentially expressed (roughly 800 in each run) if they had
a conﬁdence interval completely outside of [−τ,τ], and as not
differentially expressed if the conﬁdence interval was completely
inside of [−τ,τ]. Genes with conﬁdence intervals that contained
−τ or τ, about 9% of genes for each run, were omitted from the
analysis. As for the simulated data, we calculated the FDR and the
area under the ROC curve for each of the six statistics for each run.
For method (4) we set the cutoff value for the adjusted p-value to
0.2, and we set the cutoff fold-change for method (5) to be 2.
As for the simulated data, the number of false discoveries for each
number of genes selected as being differentially expressed and the
area under the ROC curve for each method was averaged over the
1000 runs to provide good information on the performance of each
statistic.
Figure2showsthatTREAThasthelowestFDRofallthemethods.
Whenmorethan100genesareselected,TREATclearlyoutperforms
theothermethods. Itisonlywhenfewerthan100genesareselected,
that the FDR for the two methods based on moderated t is equal to
thatofTREAT.Table1showsthatTREAThasthehighestareaunder
the ROC curve when analysing these data, which shows thatTREAT
is the best method over the full range of number of genes selected.
TREAT proves to be the superior method for analysing these data
when the magnitude of differential expression is taken into account.
3.4 Biological data
To compare further the performance of TREAT and the moderated
t, we analysed data from Peart et al. (2005). This experiment was
designed to investigate histone deacetylase inhibitors (HDACis),
in particular their effects on gene regulation in a tumorigenic cell
line over a 16h time course. The cDNA microarrays were used
to compare gene expression at ﬁve different time points (1, 2,
4, 8 and 16h) after treatment by two HDACis, suberoylanilide
hydroxamic acid (SAHA) and depsipeptide, to gene expression
(GOs) in untreated cells.
Of particular, interest are genes which respond differently over
time to the two HDACis. As described by Peart et al. (2005),
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Fig. 2. FDRs for six different gene selection statistics from the analysis
of real experimental data. The dataset was produced by a quality control
experiment conducted at the Peter MacCallum Cancer Centre. The rates are
the means of the actual FDRs from 1000 analyses of pairs of arrays selected
at random from the 99 replicate arrays in the dataset.
we used an interaction model to compare the response to SAHA
versus the response to depsipeptide at the 16h point. The analysis
was done using the limma software package (Smyth, 2005) for R
(R Development Core Team, 2006), controlling the FDR at 0.05
using the Benjamini and Hochberg (1995) method. For the TREAT
statistic, the threshold log-fold-change was set to τ =log21.1. This
threshold, corresponding to 10% fold-change, was chosen based
on our experience that fold-changes so small are virtually never
of scientiﬁc interest, and also because this cutoff gives a similar
number of DE genes to the 1.5 fold-change cutoff used by Peart
et al. (2005).
Moderated t identiﬁed 982 genes as having a signiﬁcantly higher
response to SAHAthan to depsipeptide at 16h, and 1043 genes with
signiﬁcantly lower response in SAHA versus depsipeptide at 16h.
As expected, TREAT found somewhat fewer genes as signiﬁcant,
646 higher and 674 lower at 16 h (Table 2).
To give an indication of how many genes are of genuine interest,
we checked which genes signiﬁcant at 16h were also detectable
at 8h. We checked differential expression without regard to fold-
change at 8h. Of the genes found by moderated t, 271/982 genes
were already up at 8h and 216/1043 genes found to already down
at 8h. For genes found by TREAT, 280/646 were already up at 8h
and 204/674 were already down at 8h. TREAT gives a much better
overlap between 8 and 16h than does moderated t, ﬁnding just as
many overlapping genes on a smaller base (Table 2). As genes of
genuine interest are likely to give consistent results over several
consecutive times, we conclude that TREAT does a better job of
identifying the most important responding genes.
In order to compare the biological information provided by
TREAT and moderated t, we used a DAVID search (Dennis et al.,
Table 2. Number of genes identiﬁed by moderated t and TREAT as having
higher or lower response to SAHA versus depsipeptide at 16h, and the
number of these genes also detected at the previous time point 8h
Method Direction 16h 8h Overlap (%)
Moderated t Up 982 271 27.6
Down 1043 216 20.7
TREAT Up 646 280 43.3
Down 674 204 30.3
The data come from a biological experiment investigating HDACis. The ﬁnal column
givestheproportionofgenesdifferentiallyexpressedat16hthatwerealsodifferentially
expressed at 8h.
Table 3. Relevant gene ontology groups from the analysis of the HDACi
data that were identiﬁed as signiﬁcant when using TREAT, but not when
using moderated t
Relevant gene ontology groups identiﬁed by TREAT, but not moderated t
DNA metabolic process
DNA damage
DNA repair
Response to DNA damage stimulus
Response to endogenous stimulus
Response to stress
Regulation of apoptosis
Regulation of programmed cell death
These are typically key processes in assessing responses to HDACis. Groups were
found using a DAVID search from the lists of signiﬁcantly differentially expressed
genes found using the two methods. Ontologies were found to be signiﬁcant if they had
an FDR <5%.
2003) to ﬁnd relevant gene ontologies (GOs) from the lists of
signiﬁcantly differentially expressed genes at 16h. The DAVID tool
conducts a statistical test based on Fisher’s Exact test to measure
gene-enrichment in annotation terms. The tool also reports FDRs,
calculated in a way similiar to the approximate FDR described by
Benjamini and Hochberg (1995). In our analysis, GO categories
were judged to be signiﬁcant if they had a reported FDR <5%.
TREAT and moderated t identiﬁed mostly the same GO categories.
However, TREAT was successful at identifying a number of highly
relevant GO categories which were missed by moderated t. These
interesting gene ontology groups included DNA metabolic process,
DNA damage, response to DNA damage stimulus, response to
stress, DNA repair, response to endogenous stimulus, regulation of
apoptosis and regulation of programmed cell death (Table 3). These
are typically key processes in investigating responses to HDACis
(Peart et al., 2005). No interesting categories were identiﬁed by
moderated t but not by TREAT. We conclude that the larger list
of genes returned by moderated t dilutes the biological results
somewhat by including more genes with small fold-changes.
4 DISCUSSION
The results from our analysis of the simulated and PMCC datasets
show that the traditional t-test is by far the worst and TREAT
is the best of the methods considered at ranking genes in terms
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of evidence for differential expression, when the magnitude of
differential expression is taken into account. TREAT outperforms
other methods which select genes on fold-change or which combine
t-tests and fold-changes in various ways. TREAT has the lowest
FDR and greatest area under the ROC curve for both simulated and
PMCC data. Our functional analysis of the biological data shows
that the information about gene ontologies provided by TREAT is
more focused than that provided by moderated t, in that TREAT
identiﬁes the same biologically informative genes with less dilution
by uninteresting genes.
A further advantage of TREAT is that it provides valid p-values
for any threshold value. None of its closest competitors in terms
of gene rankings [methods (3)–(5) here] give p-values at all. The
p-values provided by TREAT can be adjusted for multiple testing to
provide control of the family wise error rate or the FDR, particularly
useful in the microarray context.
Itisinterestingtonoteaconnectionwiththetheoryofequivalence
testing (Wellek, 2002), which also considers thresholded null
hypotheses similar to those considered here. In equivalence testing,
however,theroleofthenullandalternativehypothesesarereversed,
with the emphasis on proving, for example, that two drugs are
bioequivalent.Inthemicroarraycontextconsideredhere,wewishto
retain the traditional hypothesis testing view that the null hypothesis
is the status quo.
The p-values returned by TREAT are larger than those from the
moderated t-statistic, and usually although not always larger than
those from other methods which test the hypothesis that the true
differentialexpressioniszero.Atﬁrstglancethismightseemtoshow
that TREAT is less powerful than conventional tests, but in reality
TREAT is testing a different hypothesis. TREAT requires stronger
evidence of differential expression, including a sufﬁciently large
fold-change, to identify a gene as signiﬁcant, than does moderated
t or similar methods. Thus, while TREAT generally returns fewer
genes than conventional tests, TREAT offers greater speciﬁcity for
identifying the most important genes.
TREAT returns slightly conservative p-values, an inevitable side-
effect of testing a composite null hypothesis. This means that the
true FDR is likely to be better than the nominal rate suggested
by the p-values. An unavoidable consequence is that the TREAT
p-values do not follow perfectly the traditional uniform distribution
for genes which are genuinely not differentially expressed. Rather,
the null distribution of the TREAT p-values is somewhat skewed
towards larger values. While TREAT p-values can be used with
most multiple testing adjustment schemes, including Benjamini and
Hochberg(1995),theydonotfulﬁltheassumptionsofsomemethods
which try to estimate the proportion of truly null genes such as
Ferkingstad et al. (2005).
The TREAT fold-change threshold should be set to a low value
below which no fold-change is likely to be of genuine interest.
Researchers should be mindful that genes will need to exceed this
thresholdbysomeway,dependingonthedata,beforebeingdeclared
statistically signiﬁcant. Our experience suggests a minimal value,
such as a 10% fold-change, corresponding to τ =log2(1.1)=0.13
on the log2-scale. It would be better to interpret the threshold as
‘the fold-change below which we are deﬁnitely not interested in the
gene’rather than ‘the fold-change above which we are interested in
the gene’.
The TREAT threshold can be varied as appropriate for the
data at hand. If the molecular perturbation being studied produces
dramatic and promiscuous expression changes, then a relatively
large threshold may be appropriate to narrow down the search
to those genes and pathways of most inﬂuence. For example,
Peart et al. (2005) found >40% of all genes on the genome changing
at a 5% FDR. Gene knock-out experiments also often produce clear-
cut phenotypes and large differential expression changes, although
perhaps restricted to a smaller number of genes. On the other hand,
if the expression changes in the dataset are more subtle then a
small threshold (or even no threshold) can be used. For example,
physiological variations may be associated with molecular changes
which might be widespread, but are small in magnitude. If the
threshold level is set to zero, then TREAT reduces to the moderated
t-statistic presented by Smyth (2004).
TREAT is the best method when the magnitude of the differential
expression is taken into account. TREAT offers advantages over
existing methods by providing a formal hypothesis test and rigorous
associated p-values, achieved by conditioning on an ancillary
statistic. TREAT should prove especially useful in analysing
microarray experiments in which there is a large amount of
differentialexpressionbytestingformallyfordifferentialexpression
that is not only statistically signiﬁcant but also biologically
meaningful.
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